thymine has been researched along with Cancer of Esophagus in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Among FTD/TPI-treated patients, frequencies of any-cause grade ≥ 3 adverse events (AEs) were similar across age subgroups (80% each), although grade ≥ 3 neutropenia was more frequent in older patients [40% (≥ 65 and ≥ 75 years); 29% (< 65 years)]; AE-related discontinuation rates did not increase with age [14% (< 65 years), 12% (≥ 65 years), and 12% (≥ 75 years)]." | 3.11 | Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). ( Alsina, M; Benhadji, KA; Cicin, I; Doi, T; Hosaka, H; Ilson, DH; Longo, F; Makris, L; Özgüroğlu, M; Ozyilkan, O; Park, D; Pericay, C; Santoro, A; Shitara, K; Thuss-Patience, P; Zaanan, A, 2022) |
| " Common treatment-related adverse events of grade 3 or worse were neutrophil count decreased (27 [82%] in cohort A and 23 [74%] in cohort B), white blood cell count decreased (eight [24%] and seven [23%]), and platelet count decreased (eight [24%] and four [13%])." | 3.01 | Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial. ( Amagai, K; Ando, T; Fujita, J; Fujitani, K; Hosaka, H; Kawazoe, A; Koeda, K; Nishikawa, K; Ogata, K; Shitara, K; Watanabe, K; Yamamoto, Y, 2021) |
| "Oesophageal cancer is the fifth most frequent cause of cancer death world wide and most of these cancers occur in developing countries." | 2.40 | Molecular precursor lesions in oesophageal cancer. ( Hainaut, P; Montesano, R, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shitara, K | 2 |
| Doi, T | 1 |
| Hosaka, H | 2 |
| Thuss-Patience, P | 1 |
| Santoro, A | 1 |
| Longo, F | 1 |
| Ozyilkan, O | 1 |
| Cicin, I | 1 |
| Park, D | 1 |
| Zaanan, A | 1 |
| Pericay, C | 1 |
| Özgüroğlu, M | 1 |
| Alsina, M | 1 |
| Makris, L | 1 |
| Benhadji, KA | 1 |
| Ilson, DH | 1 |
| Kawazoe, A | 1 |
| Ando, T | 1 |
| Fujita, J | 1 |
| Koeda, K | 1 |
| Nishikawa, K | 1 |
| Amagai, K | 1 |
| Fujitani, K | 1 |
| Ogata, K | 1 |
| Watanabe, K | 1 |
| Yamamoto, Y | 1 |
| Montesano, R | 1 |
| Hainaut, P | 1 |
| Fabrikant, JI | 1 |
1 review available for thymine and Cancer of Esophagus
| Article | Year |
|---|---|
Molecular precursor lesions in oesophageal cancer.
Topics: Adenine; Adenocarcinoma; Base Pairing; Carcinoma, Squamous Cell; Clone Cells; Disease Progression; E | 1998 |
2 trials available for thymine and Cancer of Esophagus
| Article | Year |
|---|---|
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esoph | 2022 |
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Topics: Adenocarcinoma; Administration, Intravenous; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic | 2021 |
1 other study available for thymine and Cancer of Esophagus
| Article | Year |
|---|---|
The kinetics of cellular proliferation in human tissues. Determination of duration of DNA synthesis using double labeling autoradiography.
Topics: Autoradiography; Carbon Isotopes; Cell Division; DNA; Esophageal Neoplasms; Esophagus; Humans; In Vi | 1970 |